In contrast, the traditional i.m.-inactivated seasonal human influenza vaccine provides 10–60% efficacy and induces strain-specific immunity by generation of subtype specific Abs so that repeated annual vaccination to match new influenza variants is required (1–3). The gene discussed is DDX41; the disease is influenza.